Online inquiry

IVTScrip™ mRNA-Anti-IGF, MEDI-573(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ11372MR)

This product GTTS-WQ11372MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets IGF1&IGF2 gene. The antibody can be applied in Breast Cancer research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_000618.5; NM_000612.6
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3479; 3481
UniProt ID P05019; P01344
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IGF, MEDI-573(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ11372MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ10330MR IVTScrip™ mRNA-Anti-ERBB3, LJM716(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA LJM716
GTTS-WQ6516MR IVTScrip™ mRNA-Anti-ALCAM, CX-191(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA CX-191
GTTS-WQ5040MR IVTScrip™ mRNA-Anti-GLP1R, CA Exendin-4(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA CA Exendin-4
GTTS-WQ7989MR IVTScrip™ mRNA-Anti-GHR, GX-H9(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA GX-H9
GTTS-WQ13990MR IVTScrip™ mRNA-Anti-GP, REGN-3470-3471-3479(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA REGN-3470-3471-3479
GTTS-WQ4602MR IVTScrip™ mRNA-Anti-KIR2DL1&KIR2DL2&KIR2DL3&KIR2DS1&KIR2DS2, BMS-986015(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA BMS-986015
GTTS-WQ10473MR IVTScrip™ mRNA-Anti-SOST, LY2541546(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA LY2541546
GTTS-WQ15399MR IVTScrip™ mRNA-Anti-HAVCR2, TSR-022(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA TSR-022
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW